Tuesday 16 June 2026

One To Watch

IMIDomics

A biotechnology company focused on patient-centric drug discovery for immune-mediated inflammatory diseases (IMIDs).

Company Overview

Want to Update your Company's Profile?


Latest IMIDomics News

Formation Bio licenses program from IMIDomics
30 July 2025
UCB takes stake in immune-mediated disease specialist
5 March 2024
More IMIDomics news >


Today's issue

Reunion Neuroscience names Sahil Kirpekar as new CEO
Biotechnology
Reunion Neuroscience names Sahil Kirpekar as new CEO
16 June 2026
Pharmaceutical
Russia may revise patent protection terms for original drugs
16 June 2026
Biotechnology
Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
15 June 2026
Pharmaceutical
Grifols launches Fesilty in USA for rare bleeding disorder
15 June 2026
Biotechnology
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study
15 June 2026
Pharmaceutical
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH
15 June 2026
Biotechnology
J&J’s Talvey combo cuts progression risk in earlier myeloma setting
15 June 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze